Next Article in Journal
Unraveling Structural Wonders: Recent Advances in Biomolecular Structures
Previous Article in Journal
A Computational Study on Gold and Silver Nanoparticles against SARS-CoV-2 Proteins
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Proceedings
Volume 103
Issue 1
10.3390/proceedings2024103024
proceedings-logo
Submit to this Journal
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Production of Antibodies Binding Murine Nuclear PD-L1 †

by
Valentina Kostenko
1,2,*,
Alina Makarova
1,2,
Elena Svirshchevskaya
2,
Roman Kholodenko
2,
Dmitry Ryazantsev
2 and
Ekaterina Ryabukhina
2
1
Immunology Department, Biology Faculty, Lomonosov Moscow State University, Moscow 119991, Russia
2
Immunology Department, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia
*
Author to whom correspondence should be addressed.
†
Presented at the 3rd International Electronic Conference on Biomolecules, 23–25 April 2024; Available online: https://sciforum.net/event/IECBM2024.
Proceedings 2024, 103(1), 24; https://doi.org/10.3390/proceedings2024103024
Published: 12 April 2024
(This article belongs to the Proceedings of The 3rd International Electronic Conference on Biomolecules)
Versions Notes

Abstract

:
PD1/PD-L1 antibody therapy is used in the clinic (atezolizumab, avelumab, durvalumab), but its effect is ambiguous, both in patients and in mouse models. The purpose of this work was to analyze the binding of commercial and laboratory-obtained monoclonal antibodies to PD-L1. Previously, we obtained monoclonal antibodies (clone B12) to the extracellular fragment of murine PD-L1 expressed in E. Coli (exPD-L1). The primary screening of monoclonal antibodies by flow cytometry showed a low B12 binding compared to commercial antibodies. Cytokine-stimulated 3D cultures, permeabilized cells, and Western blotting were used to elucidate the causes of low binding on living cells. The permeabilization of cells B16/F10 (mouse melanoma), EL-4 (mouse lymphoma), and COLO357 (human pancreatic cancer) showed the binding of both mouse and human B12 PD-L1 antibodies. With the help of Western blotting, these data were confirmed. However, commercial antibodies (BioLegend, clone 10F.9G2) in this method did not bind to the mouse recombinant exPD-L1 protein, but bound to cell lysates. Cell cultivation on an anti-adhesive polyHEMA substrate led to the binding of B12 antibodies to the surface of cells under 3D cultivation conditions. The stimulation of EL-4 and B16/F10 cells in 3D cultures and subsequent incubation with Cy3-labeled B12 antibodies led to the appearance of pronounced fluorescence in the perinuclear region of cells. Thus, the obtained monoclonal antibodies to mouse exPD-L1 are cross-reactive with human PD-L1 protein; PD-L1 protein translocates to the cell membrane when cultured under 3D conditions into the nucleus and, when stimulated by cytokines, its biosynthesis is activated. The difference in the binding of antibodies B12 and 10F.9G2 may indicate a difference in the conformation of PD-L1 translocated to the membrane. The traffic of intracellular PD-L1 into the nucleus upon activation may indicate the launch of de novo protein synthesis with an altered conformation.

 

Author Contributions

V.K., in vitro cultures, confocal microscopy; A.M., production of anti-PD-L1-Cy3 conjugates, PAAG electrophoresis; E.S., concept, writing, confocal microscopy, anti-PD-L1 production, purification; R.K., anti-PD-L1-Cy3 conjugate analysis, flow cytometry; D.R., PD-L1 gene expression; E.R., PD-L1 protein purification and analysis. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Russian Scientific Fund, № 23-14-00277.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are openly available in reference [1].

Conflicts of Interest

Authors declare no conflict of interest.

Reference

  1. Goryunova, M.C.; Ryazantsev, D.Y.; Petrova, E.E.; Kostenko, V.V.; Makarova, A.O.; Kholodenko, R.V.; Ryabukhina, E.V.; Kalinovsky, D.V.; Kotsareva, O.D.; Svirshchevskaya, E.V. Expression of extracellular fragment of murine PD-L1 and production of antibodies to PD-L1. Russ. J. Bioorganic Chem. 2024, in press. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kostenko, V.; Makarova, A.; Svirshchevskaya, E.; Kholodenko, R.; Ryazantsev, D.; Ryabukhina, E. Production of Antibodies Binding Murine Nuclear PD-L1. Proceedings 2024, 103, 24. https://doi.org/10.3390/proceedings2024103024

AMA Style

Kostenko V, Makarova A, Svirshchevskaya E, Kholodenko R, Ryazantsev D, Ryabukhina E. Production of Antibodies Binding Murine Nuclear PD-L1. Proceedings. 2024; 103(1):24. https://doi.org/10.3390/proceedings2024103024

Chicago/Turabian Style

Kostenko, Valentina, Alina Makarova, Elena Svirshchevskaya, Roman Kholodenko, Dmitry Ryazantsev, and Ekaterina Ryabukhina. 2024. "Production of Antibodies Binding Murine Nuclear PD-L1" Proceedings 103, no. 1: 24. https://doi.org/10.3390/proceedings2024103024

Article Metrics

Back to TopTop